Truist Lifts PT on Teva Pharmaceutical Industries (TEVA) to $36 From $32

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best performing pharma stocks in 2025. Truist lifted the price target on Teva Pharmaceutical Industries Limited (NYSE:TEVA) to $36 from $32 on January 7 and maintained a Buy rating on the shares, telling investors that the affordable medicines theme remains attractive going into 2026.

In a separate development, Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced on December 24 that S&P Global Ratings upgraded the company’s long-term issuer credit rating to ‘BB+’ from ‘BB’ with a stable outlook. Moody’s Ratings Agency also affirmed the company’s B1a rating, revising its outlook to positive from stable

Management stated that the upgrades mark a notable milestone in Teva Pharmaceutical Industries Limited’s (NYSE:TEVA) advancement towards attaining investment-grade status. S&P noted that the company’s adjusted leverage declined to 4.4x as of September 30, 2025, and is anticipated to drop below 4.25x in the coming quarters and meet the threshold for the higher rating.

The agency also cited Teva Pharmaceutical Industries Limited’s (NYSE:TEVA) business strength, liquidity profile, and financial discipline, with it bouncing back to revenue growth following five years of declines, with support from solid performance in branded medicines and stabilization in generics.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) develops, produces, and sells medicines. Its operations are divided into the US, Europe, and International Markets geographical segments. Each business segment covers the entire product portfolio in that region, including specialty, generics, and over-the-counter (OTC) products.

While we acknowledge the potential of TEVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.